abrdn plc Makes New Investment in Caribou Biosciences, Inc. (NASDAQ:CRBU)

abrdn plc purchased a new stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 181,487 shares of the company’s stock, valued at approximately $1,040,000.

Several other institutional investors have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its holdings in Caribou Biosciences by 352.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,226 shares of the company’s stock valued at $59,000 after acquiring an additional 7,968 shares during the period. Mutual Advisors LLC purchased a new position in Caribou Biosciences during the 3rd quarter worth $83,000. State Board of Administration of Florida Retirement System lifted its holdings in shares of Caribou Biosciences by 32.0% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 21,320 shares of the company’s stock worth $102,000 after buying an additional 5,170 shares during the period. Principal Financial Group Inc. raised its holdings in shares of Caribou Biosciences by 32.8% in the third quarter. Principal Financial Group Inc. now owns 25,198 shares of the company’s stock valued at $120,000 after acquiring an additional 6,227 shares in the last quarter. Finally, E Fund Management Co. Ltd. bought a new position in Caribou Biosciences during the 3rd quarter worth about $125,000. Institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Trading Up 1.9 %

NASDAQ:CRBU opened at $3.78 on Tuesday. The company’s 50 day moving average is $5.46 and its two-hundred day moving average is $5.43. The company has a market cap of $341.41 million, a PE ratio of -2.61 and a beta of 2.48. Caribou Biosciences, Inc. has a twelve month low of $3.44 and a twelve month high of $8.59.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings results on Monday, March 11th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.17). Caribou Biosciences had a negative net margin of 296.05% and a negative return on equity of 31.06%. The firm had revenue of $3.56 million for the quarter, compared to analysts’ expectations of $5.17 million. As a group, analysts expect that Caribou Biosciences, Inc. will post -1.76 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright increased their target price on Caribou Biosciences from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Tuesday, March 19th.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.